Publication | Closed Access

5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells

Overcome Multidrug ResistanceOncogenic AgentMedicinePharmacologyColorectal CancerAnticancer ActivityColorectal Cancer CellsAnti-cancer AgentCancer BiologyCell BiologyCancer ResearchDrug DiscoveryDrug Resistance